Poly Medicure Limited
Poly Medicure Limited Fundamental Analysis
Poly Medicure Limited (POLYMED.NS) shows moderate financial fundamentals with a PE ratio of 38.88, profit margin of 19.52%, and ROE of 12.60%. The company generates $17.8B in annual revenue with strong year-over-year growth of 21.37%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 66.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze POLYMED.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakPOLYMED.NS struggles to generate sufficient returns from assets.
Valuation Score
ModeratePOLYMED.NS shows balanced valuation metrics.
Growth Score
ExcellentPOLYMED.NS delivers strong and consistent growth momentum.
Financial Health Score
ExcellentPOLYMED.NS maintains a strong and stable balance sheet.
Profitability Score
WeakPOLYMED.NS struggles to sustain strong margins.
Key Financial Metrics
Is POLYMED.NS Expensive or Cheap?
P/E Ratio
POLYMED.NS trades at 38.88 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, POLYMED.NS's PEG of -9.37 indicates potential undervaluation.
Price to Book
The market values Poly Medicure Limited at 4.63 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 26.41 times EBITDA. This signals the market has high growth expectations.
How Well Does POLYMED.NS Make Money?
Net Profit Margin
For every $100 in sales, Poly Medicure Limited keeps $19.52 as profit after all expenses.
Operating Margin
Core operations generate -4.02 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $12.60 in profit for every $100 of shareholder equity.
ROA
Poly Medicure Limited generates $9.69 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Poly Medicure Limited generates limited operating cash flow of $914.70M, signaling weaker underlying cash strength.
Free Cash Flow
Poly Medicure Limited generates weak or negative free cash flow of $-659.09M, restricting financial flexibility.
FCF Per Share
Each share generates $-6.50 in free cash annually.
FCF Yield
POLYMED.NS converts -0.49% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
38.88
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-9.37
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.63
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.59
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.08
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.89
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.10
vs 25 benchmark
ROCE
Return on capital employed
-0.02
vs 25 benchmark
How POLYMED.NS Stacks Against Its Sector Peers
| Metric | POLYMED.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 38.88 | 28.45 | Worse (Expensive) |
| ROE | 12.60% | 763.00% | Weak |
| Net Margin | 19.52% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.08 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 3.89 | 2795.60 | Strong Liquidity |
| ROA | 9.69% | -16588.00% (disorted) | Weak |
POLYMED.NS outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Poly Medicure Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
116.12%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
214.09%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
63.86%
Industry Style: Defensive, Growth, Innovation
High Growth